Explore
Validate
Learn
Western blot
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-18522 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Leptin Receptor Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with canine based on sequence homology.
- Reactivity
- Human, Mouse, Rat
- Host
- Goat
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Silicified collagen scaffold induces semaphorin 3A secretion by sensory nerves to improve in-situ bone regeneration.
Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity.
Ma YX, Jiao K, Wan QQ, Li J, Liu MY, Zhang ZB, Qin W, Wang KY, Wang YZ, Tay FR, Niu LN
Bioactive materials 2022 Mar;9:475-490
Bioactive materials 2022 Mar;9:475-490
Epiregulin as an Alternative Ligand for Leptin Receptor Alleviates Glucose Intolerance without Change in Obesity.
Song NJ, Lee A, Yasmeen R, Shen Q, Yang K, Kumar SB, Muhanna D, Arnipalli S, Noria SF, Needleman BJ, Hazey JW, Mikami DJ, Ortega-Anaya J, Jiménez-Flores R, Prokop J, Ziouzenkova O
Cells 2022 Jan 26;11(3)
Cells 2022 Jan 26;11(3)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot staining of Human Brain lysate using Product # PA5-18522 at a concentration of 1.0 µg/mL, the primary antibody incubation was 1 hour and the detection method was chemiluminescence.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Leptin Receptor by a Leptin Receptor monoclonal antibody (Product # PA5-18522) at a concentration of 0.1 µg/mL. Mouse (A) and Rat (B) Brain lysate (35µg protein in RIPA buffer). Detected by chemiluminescence.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Leptin Receptor in paraffin embedded human liver using a Leptin Receptor polyclonal antibody (Product #PA5-18522) at a concentration of 4 µg/mL. Steamed antigen retrieval was performed with pH 6 buffered citrate. Samples were then stained with alkaline phosphatase.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 4 Immunofluorescence staining of defect areas at 6 weeks after surgery. ( A ) Representative images of immunofluorescence staining of CGRP and LepR. ( B ) Representative images of CGRP and Emcn staining. ( C ) Representative images of CGRP and CD31 staining. ( D ) Quantification of CGRP, LepR, Emcn and CD31 median fluorescence intensity (MFI) per field view. Nuclei were stained with DAPI (blue). Scale bar: 100 mum. Data represent means +- standard deviations (n = 6). For all charts, groups labeled with different lowercase letters are significantly different (p < 0.05). Fig. 4
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 7 Sensory nerve-derived Sema3A promotes osteogenesis and angiogenesis in SCS-mediated bone regeneration. ( A ) Micro-CT analysis of bone regeneration at 12 weeks. 3D reconstructed superficial and interior images of femoral condyle defects in different groups. Scale bar: 4 cm. ( B ) Quantitative analysis of bone volume/total volume (TV/BV), bone mineral density (BMD) and Trabecular Thickness (Tb.Th) (n = 6). ( C ) Representative images of immunofluorescence staining of Leptin Receptor and CGRP. ( D ) Representative images of immunofluorescence staining of CGRP and Emcn. ( E ) Representative images of immunofluorescence staining of CGRP and CD31. ( F ) Quantification of CGRP, LepR, Emcn and CD31 median fluorescence intensity (MFI) per field view. Nuclei were stained with DAPI (blue). Scale bar: 100 mum. For all charts, data represent means +- standard deviations (n = 6). Groups labeled with different lowercase letters are significantly different (p < 0.05). Fig. 7
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 EREG regulated glucose uptake via binding with LepR in Lep ob mice. ( A ) EREG and insulin tolerance test in Lep ob mice ( n = 5 per group) treated with a single intraperitoneal injection of insulin (0.012 IU/g BW, triangle dashed line) or EREG (80 ng/g BW, closed circles. Asterisks, significant (* p < 0.05) compared to glucose levels before EREG treatment. # Hashtag, significant difference in glucose levels 30 min after treatment with EREG or insulin. Unpaired Student's t -test. ( B ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student's t -test, ns . ( C ) GTT kinetics were measured in Lep ob mice ( n = 5 per treatment) treated with a single injection of PBS (Veh, open circles) or EREG (closed circles). Student's t -test. * p < 0.05 from comparison between control and EREG treated mice at each time point. ( D ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student's t -test. ( E , F ). Immunoprecipitation of LepR was performed with anti-EREG antibody using homogenates from subcutaneous fat ( C ) and visceral fat ( D ). Fat tissue was isolated from non-treated Lep ob (Veh) as well as Lep ob mice 15 min after injection of EREG (50 ng/mL).
